Literature DB >> 16226495

Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.

Laura Dickinson1, Lesley Robinson, John Tjia, Saye Khoo, David Back.   

Abstract

We report a precise and accurate method for simultaneous quantification of protease inhibitors (PIs) amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in plasma. An internal standard was added to samples prior to protein precipitation with acetonitrile followed by addition of ammonium formate buffer. Analysis was by HPLC-MS/MS. Calibration curves were validated over concentration ranges encompassing both subtherapeutic and potentially 'toxic' drug concentrations. Inter- and intra-assay variation were below 11% and PI recovery was above 87%. The bioanalytical method described is successfully applied to measure PI concentrations obtained from clinical pharmacokinetic studies and routine therapeutic drug monitoring (TDM).

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16226495     DOI： 10.1016/j.jchromb.2005.09.032

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN： 1570-0232            Impact factor:   3.205


  16 in total

1.  Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.

Authors:  Alessandro Schipani; Marco Siccardi; Antonio D'Avolio; Lorena Baietto; Marco Simiele; Stefano Bonora; Sonia Rodríguez Novoa; Lorena Cuenca; Vincent Soriano; Nitipatana Chierakul; Natpratou Saguenwong; Charoen Chuchuttaworn; Janelle M Hoskins; Anne M Dvorak; Howard L McLeod; Gerry Davies; Saye Khoo; David J Back; Giovanni Di Perri; Andrew Owen
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.

Authors:  C Kityo; A S Walker; L Dickinson; F Lutwama; J Kayiwa; F Ssali; R Nalumenya; D Tumukunde; P Munderi; A Reid; C F Gilks; D M Gibb; S Khoo
Journal:  Antimicrob Agents Chemother       Date:  2010-04-26       Impact factor: 5.191

3.  Quantitative immunoassay to measure plasma and intracellular atazanavir levels: analysis of drug accumulation in cultured T cells.

Authors:  Camille Roucairol; Stéphane Azoulay; Marie-Claire Nevers; Christophe Créminon; Thibault Lavrut; Rodolphe Garraffo; Jacques Grassi; Alain Burger; Danièle Duval
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

4.  Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients.

Authors:  Leonardo Calza; Laura Mosca; Daria Pocaterra; Benedetta Piergentili; Vincenzo Colangeli; Roberto Manfredi; Annalisa Erario; Gabriele Grossi; Gabriella Verucchi; Pierluigi Viale
Journal:  Eur J Clin Pharmacol       Date:  2010-09-28       Impact factor: 2.953

5.  UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.

Authors:  Jiangeng Huang; Nagsen Gautam; Sai Praneeth R Bathena; Upal Roy; JoEllyn McMillan; Howard E Gendelman; Yazen Alnouti
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-07-01       Impact factor: 3.205

6.  Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir.

Authors:  R J Caswell; D Phillips; M Chaponda; S H Khoo; G P Taylor; M Ghanem; M Poulton; J Welch; S Gibbons; V Jackson; J S Lambert
Journal:  Int J STD AIDS       Date:  2011-01       Impact factor: 1.359

7.  HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.

Authors:  Ruben C Hartkoorn; Wai San Kwan; Victoria Shallcross; Ammara Chaikan; Neill Liptrott; Deirdre Egan; Enrique Salcedo Sora; Chloë E James; Sara Gibbons; Pat G Bray; David J Back; Saye H Khoo; Andrew Owen
Journal:  Pharmacogenet Genomics       Date:  2010-02       Impact factor: 2.089

8.  Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals.

Authors:  Laura Dickinson; Marta Boffito; David J Back; Saye H Khoo; Anton L Pozniak; Peter Mugyenyi; Concepta Merry; Reshma Saskia Autar; David M Burger; Leon J Aarons
Journal:  J Antimicrob Chemother       Date:  2008-09-29       Impact factor: 5.790

9.  Lopinavir/ritonavir pharmacokinetics in HIV/HCV-coinfected patients with or without cirrhosis.

Authors:  Valeria Micheli; Mario Regazzi; Laura Dickinson; Paola Meraviglia; Paola Villani; Saye H Khoo; Paolo Viganò; Laura Cordier; Maria Cusato; Piergiorgio Duca; Giovanna Orlando; Giuliano Rizzardini; David J Back; Antonietta Cargnel
Journal:  Ther Drug Monit       Date:  2008-06       Impact factor: 3.681

10.  Factors influencing lopinavir and atazanavir plasma concentration.

Authors:  Wolfgang Stöhr; David Back; David Dunn; Caroline Sabin; Alan Winston; Richard Gilson; Deenan Pillay; Teresa Hill; Jonathan Ainsworth; Brian Gazzard; Clifford Leen; Loveleen Bansi; Martin Fisher; Chloe Orkin; Jane Anderson; Margaret Johnson; Philippa Easterbrook; Sara Gibbons; Saye Khoo
Journal:  J Antimicrob Chemother       Date:  2010-01       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.